Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD

Inclusion Criteria: * Age between 50-85 years * Diagnosis of dementia of the Alzheimer's type according to the National Institute of Ageing-Alzheimer's Association Criteriah * MRI brain (with T2 or FLAIR sequences) performed within a 12 month period from time of recruitment demonstrating the presence of WMH of ≥2 on the Fazekas scale (Score range of 0-3 wherein a score of 1 indicates mild WMH, 2 indicates moderate WMH and 3 indicates severe WMH).i * Clinical Dementia Rating score of 1-2j * Mini-Mental State Examination (MMSE) scores of 12-26 inclusivek * English or Mandarin speaking, literate participants Exclusion Criteria: * Severe neurological, psychiatric or systemic disease which in the opinion of the clinician could interfere with trial assessments * The use of any investigational drugs, new psychotropic or dopaminergic agents, cholinesterase inhibitors or anti-cholinergic agents during the 4 weeks prior to recruitment * Known skin allergy or previous allergic reaction to Rivastigmine patch